医学
吉西他滨
脂质体
胰腺癌
紫杉醇
临床试验
生物制药
药理学
治疗指标
药品
癌症
肿瘤科
化疗
内科学
材料科学
生物
遗传学
纳米技术
作者
Emanuela Gentile,Felisa Cilurzo,Luisa Di Marzio,Maria Carafa,Cinzia Anna Ventura,Joy Wolfram,Donatella Paolino,Christian Celia
出处
期刊:Future Oncology
[Future Medicine]
日期:2013-12-03
卷期号:9 (12): 1849-1859
被引量:63
摘要
Currently, six liposomal chemotherapeutics have received clinical approval and many more are in clinical trials or undergoing preclinical evaluation. Liposomes exhibit low toxicity and improve the biopharmaceutical features and therapeutic index of drugs, thereby increasing efficacy and reducing side effects. In this review we discuss the advantages of using liposomes for the delivery of chemotherapeutics. Gemcitabine and paclitaxel have been chosen as examples to illustrate how the performance of a metabolically unstable or poorly water-soluble drug can be greatly improved by liposomal incorporation. We look at the beneficial effects of liposomes in a variety of solid and blood-borne tumors, including thyroid cancer, pancreatic cancer, breast cancer and multiple myeloma.
科研通智能强力驱动
Strongly Powered by AbleSci AI